The Neutrophil-to-apolipoprotein A1 Ratio is Associated with Adverse Outcomes in Patients with Acute Decompensated Heart Failure at Different Glucose Metabolic States: a Retrospective Cohort Study

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2024 Apr 22

PMID 38649986

Authors

Weimeng Cheng

Tianyue Li

Xiaohan Wang

Tingting Xu

Ying Zhang

Jianzhou Chen

Zhonghai Wei

Affiliations

Soon will be listed here.

Abstract

Background: The present study was performed to assess the association between the neutrophil-to-apolipoprotein A1 ratio (NAR) and outcomes in patients with acute decompensated heart failure (ADHF) at different glucose metabolism states.

Methods: We recruited 1233 patients with ADHF who were admitted to Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University from December 2014 to October 2019. The endpoints were defined as composites of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke and exacerbation of chronic heart failure. The restricted cubic spline was used to determine the best cutoff of NAR, and patients were divided into low and high NAR groups. Kaplan-Meier plots and multivariable Cox proportional hazard models were used to investigate the association between NAR and the risk of adverse outcomes.

Results: During the five-year follow-up period, the composite outcome occurred in 692 participants (56.1%). After adjusting for potential confounding factors, a higher NAR was associated with a higher incidence of composite outcomes in the total cohort (Model 1: HR = 1.42, 95% CI = 1.22-1.65, P<0.001; Model 2: HR = 1.29, 95% CI = 1.10-1.51, P = 0.002; Model 3: HR = 1.20, 95% CI = 1.01-1.42, P = 0.036). At different glucose metabolic states, a high NAR was associated with a high risk of composite outcomes in patients with diabetes mellitus (DM) (Model 1: HR = 1.54, 95% CI = 1.25-1.90, P<0.001; Model 2: HR = 1.40, 95% CI = 1.13-1.74, P = 0.002; Model 3: HR = 1.31, 95% CI = 1.04-1.66, P = 0.022), and the above association was not found in patients with prediabetes mellitus (Pre-DM) or normal glucose regulation (NGR) (both P>0.05).

Conclusions: The NAR has predictive value for adverse outcomes of ADHF with DM, which implies that the NAR could be a potential indicator for the management of ADHF.

References

Lee M, Luo E, Silvestre-Roig C, Srinivasan Y, Akabori K, Lemnitzer P . Apolipoprotein Mimetic Peptide Inhibits Neutrophil-Driven Inflammatory Damage via Membrane Remodeling and Suppression of Cell Lysis. ACS Nano. 2021; 15(10):15930-15939. PMC: 8720511. DOI: 10.1021/acsnano.1c03978. View

Stenkula K, Lindahl M, Petrlova J, Dalla-Riva J, Goransson O, Cushman S . Single injections of apoA-I acutely improve in vivo glucose tolerance in insulin-resistant mice. Diabetologia. 2014; 57(4):797-800. PMC: 3940850. DOI: 10.1007/s00125-014-3162-7. View

Colombo P, Onat D, Harxhi A, Demmer R, Hayashi Y, Jelic S . Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J. 2013; 35(7):448-54. PMC: 3924182. DOI: 10.1093/eurheartj/eht456. View

Chen J, Normand S, Wang Y, Krumholz H . National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA. 2011; 306(15):1669-78. PMC: 3688069. DOI: 10.1001/jama.2011.1474. View

Linton M, Yancey P, Tao H, Davies S . HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy. Circ Res. 2023; 132(11):1521-1545. PMC: 10213997. DOI: 10.1161/CIRCRESAHA.123.321563. View

Woo S, Ahn S, Ahn J, Park K, Lee K . Elevated systemic neutrophil count in diabetic retinopathy and diabetes: a hospital-based cross-sectional study of 30,793 Korean subjects. Invest Ophthalmol Vis Sci. 2011; 52(10):7697-703. DOI: 10.1167/iovs.11-7784. View

Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss D . Neutrophil extracellular traps kill bacteria. Science. 2004; 303(5663):1532-5. DOI: 10.1126/science.1092385. View

Yap J, Irei J, Lozano-Gerona J, Vanapruks S, Bishop T, Boisvert W . Macrophages in cardiac remodelling after myocardial infarction. Nat Rev Cardiol. 2023; 20(6):373-385. DOI: 10.1038/s41569-022-00823-5. View

Murphy A, Woollard K, Suhartoyo A, Stirzaker R, Shaw J, Sviridov D . Neutrophil activation is attenuated by high-density lipoprotein and apolipoprotein A-I in in vitro and in vivo models of inflammation. Arterioscler Thromb Vasc Biol. 2011; 31(6):1333-41. DOI: 10.1161/ATVBAHA.111.226258. View

10.

Gombos T, Forhecz Z, Pozsonyi Z, Janoskuti L, Prohaszka Z, Karadi I . Long-Term Survival and Apolipoprotein A1 Level in Chronic Heart Failure: Interaction With Tumor Necrosis Factor α -308 G/A Polymorphism. J Card Fail. 2016; 23(2):113-120. DOI: 10.1016/j.cardfail.2016.06.004. View

11.

Li J, Wu Y, Li W, Ma J . Neutrophil to apolipoprotein A-I ratio as an independent indicator of locally advanced nasopharyngeal carcinoma. Laryngoscope Investig Otolaryngol. 2021; 6(5):1049-1061. PMC: 8513451. DOI: 10.1002/lio2.660. View

12.

Dewachter C, Belhaj A, Rondelet B, Vercruyssen M, Schraufnagel D, Remmelink M . Myocardial inflammation in experimental acute right ventricular failure: Effects of prostacyclin therapy. J Heart Lung Transplant. 2015; 34(10):1334-45. DOI: 10.1016/j.healun.2015.05.004. View

13.

Schmidt M, Duncan B, Sharrett A, Lindberg G, Savage P, Offenbacher S . Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999; 353(9165):1649-52. DOI: 10.1016/s0140-6736(99)01046-6. View

14.

McQueen M, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J . Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008; 372(9634):224-33. DOI: 10.1016/S0140-6736(08)61076-4. View

15.

Yu Y, Liu J, Zhang L, Ji R, Su X, Gao Z . Perceived Economic Burden, Mortality, and Health Status in Patients With Heart Failure. JAMA Netw Open. 2024; 7(3):e241420. PMC: 10958235. DOI: 10.1001/jamanetworkopen.2024.1420. View

16.

Wedel H, McMurray J, Lindberg M, Wikstrand J, Cleland J, Cornel J . Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail. 2009; 11(3):281-91. PMC: 2645061. DOI: 10.1093/eurjhf/hfn046. View

17.

Kraakman M, Lee M, Al-Sharea A, Dragoljevic D, Barrett T, Montenont E . Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes. J Clin Invest. 2017; 127(6):2133-2147. PMC: 5451242. DOI: 10.1172/JCI92450. View

18.

Kong M, Jang S, Jang J, Cho H, Lee S, Lee S . Impact of diabetes mellitus on mortality in patients with acute heart failure: a prospective cohort study. Cardiovasc Diabetol. 2020; 19(1):49. PMC: 7196232. DOI: 10.1186/s12933-020-01026-3. View

19.

Braunwald E . Heart failure. JACC Heart Fail. 2014; 1(1):1-20. DOI: 10.1016/j.jchf.2012.10.002. View

20.

Chen J, Chen Y, Jiang N, Xu J, Liang Z, Bai M . Neutrophil-to-Apolipoprotein A1 Ratio Predicted Overall Survival in Hepatocellular Carcinoma Receiving Transarterial Chemoembolization. Oncologist. 2021; 26(8):e1434-e1444. PMC: 8342583. DOI: 10.1002/onco.13743. View